Venous Leg Ulcer Treatment Market Report 2026

The venous leg ulcer treatment market size has grown strongly in recent years. It will grow from $4.29 billion in 2025 to $4.6 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to increasing prevalence of chronic venous insufficiency, widespread use of compression bandaging, expansion of wound care clinics, growing aging population, improved availability of topical wound treatments.

The venous leg ulcer treatment market size is expected to see strong growth in the next few years. It will grow to $6 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising demand for advanced wound healing technologies, increasing adoption of home healthcare services, expansion of minimally invasive venous procedures, growing focus on infection prevention, increasing investments in chronic wound management solutions. Major trends in the forecast period include increasing adoption of advanced compression therapy solutions, rising use of bioactive wound care products, growing focus on early intervention strategies, expansion of home-based wound management, enhanced integration of multidisciplinary care.

The growing availability of healthcare facilities is expected to drive growth in the venous leg ulcer treatment market in the coming years. Healthcare facilities refer to the essential physical infrastructure, systems, and resources required to deliver effective healthcare services. The expansion of healthcare infrastructure is driven by advancements in medical technology, as innovations such as telemedicine, robotic surgery, and AI-driven diagnostics require upgraded facilities, specialized equipment, and enhanced healthcare delivery systems to improve patient outcomes and efficiency. Healthcare facilities support venous leg ulcer treatment by providing access to modern wound care units, evidence-based therapies, trained medical professionals, and innovative treatment options, all of which contribute to faster healing and improved patient quality of life. For instance, according to the American Hospital Association, a US-based non-profit organization, the United States had a total of 6,120 hospitals in 2024, up from 6,093 hospitals in 2022. Therefore, the expanding healthcare infrastructure is fueling growth in the venous leg ulcer treatment market.

Major companies operating in the venous leg ulcer treatment market are focusing on developing advanced wound dressings using biosynthetic cellulose to enhance healing and support chronic wound management. Biosynthetic cellulose is a bioengineered material produced by microorganisms through fermentation, offering high purity, biocompatibility, and excellent strength for a variety of applications. For instance, in June 2023, Evonik Industries AG, a Germany-based specialty chemicals company, launched Epicite Balance, a wound dressing made from biosynthetic cellulose designed for the treatment of chronic wounds such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers. The dressing promotes wound healing by maintaining a moist environment, absorbing exudate, and supporting superior cleansing, making it suitable for both hospital and homecare use.

In October 2024, Mölnlycke Health Care, a Sweden-based medical technology company specializing in wound care, acquired P.G.F. Industry Solutions GmbH for an undisclosed sum. Through this acquisition, Mölnlycke aims to expand its chronic wound-care portfolio by incorporating Granudacyn, a line of wound cleansing and moistening solutions used for both acute and chronic wounds, including venous leg ulcers. P.G.F. Industry Solutions GmbH is an Austria-based manufacturer of hypochlorous acid-based wound irrigation and cleansing products designed for use across various wound types.

Major companies operating in the venous leg ulcer treatment market are 3M Healthcare, Essity AB, B. Braun Melsungen AG, Smith & Nephew plc, Coloplast A/S, Convatec Group PLC, Molnlycke Healthcare, Integra LifeSciences, Hollister Incorporated, Bioventus LLC, Medi, Kerecis, Tissue Regenix Group, The Whiteley Clinic, Huntleigh Healthcare, Derma Sciences, Systagenix Wound Management, Kinetic Concepts, Orpyx Medical Technologies.

North America was the largest region in the venous leg ulcer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the venous leg ulcer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the venous leg ulcer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the venous leg ulcer treatment market by increasing costs of imported compression devices, wound dressings, medical textiles, and advanced therapeutic products. Healthcare providers in North America and Europe are most affected due to reliance on imported wound care supplies, while Asia-Pacific faces pricing pressure on medical textile exports. These tariffs are contributing to higher treatment costs and slower adoption of advanced therapies. However, they are also promoting domestic manufacturing of wound care products, regional supplier development, and increased focus on cost-effective treatment solutions.

The venous leg ulcer treatment market research report is one of a series of new reports that provides venous leg ulcer treatment market statistics, including venous leg ulcer treatment industry global market size, regional shares, competitors with a venous leg ulcer treatment market share, detailed venous leg ulcer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the venous leg ulcer treatment industry. This venous leg ulcer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Venous leg ulcer treatment involves a comprehensive approach focused on managing and healing open sores on the legs caused by poor venous circulation. This treatment generally includes compression therapy to enhance blood flow, wound care to prevent infection, and lifestyle changes or medical interventions to address underlying venous disorders.

The main treatment approaches for venous leg ulcers include compression therapy, debridement, medication, and surgery. Compression therapy is a non-invasive method that applies pressure to the affected leg to improve circulation and reduce swelling, commonly used to promote healing and prevent recurrence of venous leg ulcers. The underlying causes include venous insufficiency, arterial insufficiency, mixed insufficiency, and others, with mechanisms of action such as oxygenation enhancers, growth factor stimulators, anti-inflammatory agents, and antimicrobial treatments. These therapies are used by various end users, including hospitals, clinics, home healthcare providers, and others.

The venous leg ulcer treatment market consists of revenues earned by entities by providing services such as infection management, and skin grafting. The market value includes the value of related goods sold by the service provider or included within the service offering. The venous leg ulcer treatment market also includes sales of compression stockings, foam dressings, skin protectants, debridement tools, and hydrocolloid dressings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.